A revolution in HCV treatment with direct-acting antivirals: From non-response to eradication

Journal of Hepatology

Volumn 57, Issue 2, 2012, Pages 455-457

  Asselah, Tarik ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Genotype 1; Immune response; Interferon free regimen; NS5A inhibitors; Null response; Protease inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; CLINICAL ARTICLE; DIARRHEA; DRUG SAFETY; FATIGUE; GENOTYPE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NAUSEA; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS MUTATION;

EID: 84863985382     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.03.005     Document Type: Note

References (15)

1. S. Zeuzem, P. Andreone, and S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
2. B.R. Bacon, S.C. Gordon, and E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
3. T. Asselah, and P. Marcellin Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow Liver Int 32 2012 88 102
4. E. Gane, S. Roberts, and C. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
5. A.S. Lok, D.F. Gardiner, and E. Lawitz Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
6. M. Gao, R.E. Nettles, and M. Belema Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
7. T. Asselah NS5A inhibitors: a new breakthrough for the treatment of chronic hepatitis C J Hepatol 54 2011 1069 1072
8. R.A. Fridell, C. Wang, and J.H. Sun Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
9. J.L. Kim, K.A. Morgenstern, and C. Lin Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide Cell 87 1996 343 355
10. R.E. Nettles, M. Gao, and M. Bifano Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 2011 1956 1965
11. C. Pasquinelli, T. Eley, and C. Villegas Safety, tolerability, pharmacokinetics and antiviral activity following single- and multiple-dose administration of BMS-650032, a novel HCV NS3 inhibitor, in subjects with chronic genotype 1 HCV infection Hepatology 50 2009 411A abstract
12. M. Bifano, H. Sevinsky, and B.R. Bedford Co-administration of BMS-790052 and BMS-650032 does not result in a clinically meaningful pharmacokinetic interaction in healthy subjects Hepatology 52 2010 719A abstract
13. M. Martinot-Peignoux, C. Stern, S. Maylin, M.P. Ripault, N. Boyer, and L. Leclere Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
14. K. Chayama, S. Takahashi, and J. Toyota Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
15. S. Zeuzem, T. Asselah, and P. Angus Efficacy of the protease inhibitor BI201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055